Tredje AP fonden Buys Shares of 30,000 Halozyme Therapeutics, Inc. $HALO

Tredje AP fonden bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,019,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Clark Capital Management Group Inc. raised its stake in Halozyme Therapeutics by 14.4% during the 3rd quarter. Clark Capital Management Group Inc. now owns 202,965 shares of the biopharmaceutical company’s stock valued at $14,885,000 after acquiring an additional 25,582 shares in the last quarter. Intech Investment Management LLC raised its stake in Halozyme Therapeutics by 46.0% during the 3rd quarter. Intech Investment Management LLC now owns 148,667 shares of the biopharmaceutical company’s stock valued at $10,903,000 after acquiring an additional 46,850 shares in the last quarter. Allworth Financial LP raised its stake in Halozyme Therapeutics by 322.5% during the 3rd quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock valued at $2,914,000 after acquiring an additional 30,331 shares in the last quarter. ING Groep NV bought a new stake in Halozyme Therapeutics during the 3rd quarter valued at $6,652,000. Finally, Element Squared LLC bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $1,193,000. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on HALO shares. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright lifted their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, Wells Fargo & Company lifted their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Halozyme Therapeutics Stock Up 0.4%

Shares of HALO stock opened at $68.98 on Thursday. Halozyme Therapeutics, Inc. has a 1 year low of $51.06 and a 1 year high of $82.22. The stock has a market cap of $8.18 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The business’s fifty day moving average is $65.69 and its 200-day moving average is $68.73. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same period last year, the firm earned $1.11 EPS. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts expect that Halozyme Therapeutics, Inc. will post 7.66 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the sale, the director directly owned 38,498 shares of the company’s stock, valued at $2,443,853.04. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the business’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total value of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares in the company, valued at $477,200.20. This trade represents a 55.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 120,482 shares of company stock valued at $8,200,842 over the last three months. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.